Celcuity Inc.
corporate_fare Company Profile
Celcuity Inc. (NASDAQ:CELC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for CELC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 13 rated 8 or above. Recent SEC coverage for CELC spans 10-Q, 8-K, SCHEDULE 13D/A, 144.
Recent high-impact activity:
- FDA Accepts sNDA for REVTORPYK in PIK3CA-Mutant Breast Cancer, PDUFA Set for June 2027
- Celcuity 10-Q: $642.7M Cash Through 2029, Q3 Loss Widens to $73.3M on Launch Costs
- Celcuity Q3 Loss Widens to $73.3M as REVTORPYK Launch Begins; $642.7M Cash Funds Through 2029
- Celcuity Q3 Loss Narrower Than Expected as Launch Spending Runs $77.3M
- Celcuity Launches REVTORPYK Commercially in the U.S. for HR+/HER2- Advanced Breast Cancer
Financial Snapshot
Short Interest & Short Volume
5.85 days to coverFINRA reported short interest of 10,303,095 shares in CELC as of the October 30, 2026 settlement, a 0.5% increase from the prior period — about 5.8 days to cover at its recent average daily volume. On November 20, 2026, 55.2% of CELC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CELC, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.
$500M Convertible Senior Notes Offering Finalized · Premium Conversion Price Demonstrates Confidence
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →